PharmaCyte Biotech (PMCB) Competitors $1.00 -0.02 (-2.17%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMCB vs. BCAB, ALXO, INKT, EGRX, CVKD, PASG, VOR, GBIO, GELS, and DAREShould you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include BioAtla (BCAB), ALX Oncology (ALXO), MiNK Therapeutics (INKT), Eagle Pharmaceuticals (EGRX), Cadrenal Therapeutics (CVKD), Passage Bio (PASG), Vor Biopharma (VOR), Generation Bio (GBIO), Gelteq (GELS), and Daré Bioscience (DARE). These companies are all part of the "pharmaceutical products" industry. PharmaCyte Biotech vs. Its Competitors BioAtla ALX Oncology MiNK Therapeutics Eagle Pharmaceuticals Cadrenal Therapeutics Passage Bio Vor Biopharma Generation Bio Gelteq Daré Bioscience PharmaCyte Biotech (NASDAQ:PMCB) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking. Does the MarketBeat Community prefer PMCB or BCAB? BioAtla received 25 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformPharmaCyte BiotechN/AN/ABioAtlaOutperform Votes2564.10% Underperform Votes1435.90% Do analysts recommend PMCB or BCAB? BioAtla has a consensus target price of $5.00, suggesting a potential upside of 1,133.05%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than PharmaCyte Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PharmaCyte Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals believe in PMCB or BCAB? 34.2% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 10.2% of PharmaCyte Biotech shares are owned by company insiders. Comparatively, 11.5% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to PMCB or BCAB? In the previous week, PharmaCyte Biotech had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for PharmaCyte Biotech and 1 mentions for BioAtla. BioAtla's average media sentiment score of 0.94 beat PharmaCyte Biotech's score of 0.44 indicating that BioAtla is being referred to more favorably in the news media. Company Overall Sentiment PharmaCyte Biotech Neutral BioAtla Positive Which has higher earnings and valuation, PMCB or BCAB? PharmaCyte Biotech has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharmaCyte BiotechN/AN/A$330K$0.741.35BioAtla$11M2.15-$123.46M-$1.22-0.33 Which has more volatility & risk, PMCB or BCAB? PharmaCyte Biotech has a beta of -0.44, indicating that its share price is 144% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Is PMCB or BCAB more profitable? PharmaCyte Biotech's return on equity of 0.76% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets PharmaCyte BiotechN/A 0.76% 0.45% BioAtla N/A -187.30%-96.33% SummaryBioAtla beats PharmaCyte Biotech on 9 of the 15 factors compared between the two stocks. Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricPharmaCyte BiotechBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.86M$3.09B$5.57B$8.50BDividend YieldN/A1.56%5.27%4.17%P/E Ratio1.8932.6326.7519.66Price / SalesN/A455.18403.98152.07Price / CashN/A168.6838.2534.64Price / Book0.313.366.964.59Net Income$330K-$72.35M$3.23B$248.23M7 Day Performance-1.96%0.36%-1.22%-1.07%1 Month Performance-3.85%16.10%6.34%2.59%1 Year Performance-53.92%-15.37%33.05%13.50% PharmaCyte Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBPharmaCyte Biotech1.2282 of 5 stars$1.00-2.0%N/A-53.9%$6.86MN/A1.894Short Interest ↑BCABBioAtla2.6379 of 5 stars$0.51-0.5%$5.00+890.1%-74.5%$29.50M$11M-0.3060ALXOALX Oncology2.8998 of 5 stars$0.55-4.8%$3.30+498.9%-93.6%$29.42MN/A-0.1840Positive NewsAnalyst RevisionGap UpINKTMiNK Therapeutics3.1129 of 5 stars$7.35+2.6%$37.50+410.6%-20.5%$29.28MN/A-1.8830Short Interest ↓Gap DownEGRXEagle PharmaceuticalsN/A$2.25flatN/A-37.7%$29.22M$257.55M0.00100CVKDCadrenal Therapeutics3.2281 of 5 stars$14.80-1.3%$32.00+116.2%N/A$29.11MN/A-2.224News CoverageShort Interest ↓Gap DownPASGPassage Bio2.7563 of 5 stars$0.47+1.2%$7.50+1,506.0%-62.8%$29.02MN/A-0.40130VORVor Biopharma2.7979 of 5 stars$0.23+2.7%$7.06+2,981.7%-84.2%$28.62MN/A-0.14140News CoverageShort Interest ↑Gap DownGBIOGeneration Bio4.0643 of 5 stars$0.42+5.8%$7.33+1,641.9%-86.5%$28.22M$24.56M-0.19150Short Interest ↓Gap UpGELSGelteqN/A$2.99+75.9%N/AN/A$28.22MN/A0.00N/AGap UpHigh Trading VolumeDAREDaré Bioscience1.3904 of 5 stars$3.15+0.6%$12.00+281.0%-43.9%$27.88M$25.91K-5.3330News Coverage Related Companies and Tools Related Companies BCAB Competitors ALXO Competitors INKT Competitors EGRX Competitors CVKD Competitors PASG Competitors VOR Competitors GBIO Competitors GELS Competitors DARE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMCB) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PMCB Stock Free PMCB Stock Alerts